Merck KGaA

📅 Upcoming

🕒 Recent(90d)

News

• EMD Serono cuts 20 at Massachusetts research site
  Follow along as BioSpace tracks job cuts and restructuring initiatives.
  biospace · 20h ago
• Merck KGaA lays off 20 staffers in latest blow to US research team
  The Massachusetts research site for Merck KGaA’s North American division, EMD Serono, has decided to hand pink slips to 20 staffers, Fierce has learned.
  fiercebiotech · 1d ago
• Lilly pens $370M deal with OmniAb for ion channel collab, but details remain vague
  Antibody platform business OmniAb continues to rack up Big Pharma partnerships, with Eli Lilly signing off on up to $370 million biobucks tied to an ion channel program.
  fiercebiotech · 2d ago
• July's biopharma layoffs affect 466 employees, a 94% year-over-year drop
  Last month, biopharmas cutting or planning to cut their workforces included Amgen, GSK and Novartis, with Novartis’ layoffs affecting the most people.
  biospace · 6d ago
• Deerfield-backed Boulevard Bio embarks on ‘beautiful path to a cure’ with trio of immunology drugs
  Boulevard Bio has strolled out of stealth with $65 million in funding from Deerfield Management and three autoimmune disease candidates.
  fiercebiotech · 7d ago
• MoonLake’s nanobody boosts all clinical endpoints in phase 3 psoriatic arthritis trial
  MoonLake Immunotherapeutics announced positive phase 3 data for patients with psoriatic arthritis treated with its lead nanobody candidate, sonelokimab.
  fiercebiotech · 9d ago
• Merck KGaA readies tariff refunds worth €40M for life science customers
  Merck KGaA said it expects to receive tariff refunds for its life science business through the end of 2026 after the US Supreme Court blocked some of President Donald Trump’s levies. The German con…
  endpoints · 12d ago
• Sanofi suspends chronic lung disease phase 2 study, tied to ‘strategic business reasons’
  Sanofi halted a phase 2 trial testing a monoclonal antibody, SAR445399, in non-cystic fibrosis bronchiectasis, Fierce has learned.
  fiercebiotech · 13d ago
• Sanofi’s new CEO ‘looking deeply’ at late-stage pipeline as clinical clearout continues
  Sanofi's new CEO Belén Garijo opened up for the first time about her strategy to reverse a trend of clinical setbacks, including dumping Regeneron-partnered IL-33 candidate itepekimab.
  fiercebiotech · 20d ago
• FDA accepts Replimune filing; Merck KGaA drops $11B on life sciences services
  Replimune’s application is the latest example of changing attitudes at the FDA. Elsewhere, Revolution Medicines outlined more RAS-blocking data and a Definium stock offering brought in $800 million.
  biopharma_dive · 1mo ago